Gellan Contact Study

NCT ID: NCT04044014

Last Updated: 2019-08-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

33 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-10-10

Study Completion Date

2017-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study will be to establish the safety of the two different Gellan formulations (sheet and fluid gel) following its application to the epidermis of healthy volunteers. This will be compared to a control dressing-- Mepitel One (Polyurethane net with soft Silicone).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This contact study is part of the Wellcome trust Anti-scarring Dressing project to develop a carrier dressing that will be used to deliver therapeutic agents to the skin. A polysaccharide, Gellan, has been chosen as the main component of this dressing (the biomembrane)and it can be produced in either a sheet or fluid gel forms. Gellan is a widely used material in both the food and medical industry e.g. as a lubricant in eye-drops (e.g. Timoptol XE, Merck Sharp \& Dohme, USA).

As part of the development of the dressing, the epidermal (skin) response to Gellan needs to be evaluated to check its safety.

The main objective of this study is to establish the safety of the two different Gellan formulations (2% Gellan sheet and 2% Gellan fluid gel) following application to the epidermis (skin).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thermal Injury Skin Burn

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Participants will be randomised to receive the treatment dressing (either the Gellan sheet or Gellan fluid gel) on one arm (Left or Right), and the control dressing (Mepitel One) on the other arm. The first phase will be for 1 hour and the 2nd phase will be for 3 days.
Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Outcome Assessors
Two assessors will be evaluating the skin for erythema, dryness and oedema. They will be blinded to which arm has received the treatment and control.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm A

Left arm: Gellan sheet; Right arm: Mepitel One.

Group Type ACTIVE_COMPARATOR

Gellan sheet

Intervention Type DEVICE

Gellan sheet.

Mepitel One

Intervention Type DEVICE

Control dressing-- Mepitel One.

Arm B

Left arm: Mepitel One; Right arm: Gellan sheet.

Group Type ACTIVE_COMPARATOR

Gellan sheet

Intervention Type DEVICE

Gellan sheet.

Mepitel One

Intervention Type DEVICE

Control dressing-- Mepitel One.

Arm C

Left arm: Gellan fluid gel; Right arm: Mepitel One.

Group Type ACTIVE_COMPARATOR

Gellan fluid gel

Intervention Type DEVICE

Gellan fluid gel.

Mepitel One

Intervention Type DEVICE

Control dressing-- Mepitel One.

Arm D

Left arm: Mepitel One; Right arm: Gellan fluid gel.

Group Type ACTIVE_COMPARATOR

Gellan fluid gel

Intervention Type DEVICE

Gellan fluid gel.

Mepitel One

Intervention Type DEVICE

Control dressing-- Mepitel One.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Gellan sheet

Gellan sheet.

Intervention Type DEVICE

Gellan fluid gel

Gellan fluid gel.

Intervention Type DEVICE

Mepitel One

Control dressing-- Mepitel One.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female subjects aged ≥ 18 years old
* Subjects who can provide informed consent

Exclusion Criteria

* Subject with existing skin conditions/diseases which may interfere with the aim(s) of the study. Examples include pathological fibrosis e.g. scleroderma; pathological thinning e.g. epidermolysis bullosa and collagen disorders e.g. Marfan's syndrome
* Chronic steroid use, history of skin malignancy or chronic papulo-squamous disease (e.g. eczema, pemphigus) and history of Steven Johnson or TENS disease
* Blemishes, marks (e.g. tattoos, scars or burns,) on the test site(s) which may interfere with assessment on the test site
* Use of medication which may affect may affect skin response
* Known allergy to the materials used in the study
* Known allergy to adhesive plasters or tapes
* Fitzpatrick skin type VI (due to the difficulty of identifying erythema)
* Irritated skin on the test site
* Known pregnancy (confirmed by urine pregnancy test) or lactating
* Inability to commit to attending all sessions.
* Participation in another study which may affect the results of this contact study.
* Any other reason that clinician considers will interfere with the objectives of the study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Wellcome Trust

OTHER

Sponsor Role collaborator

University Hospital Birmingham

OTHER

Sponsor Role collaborator

University of Birmingham

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Wellcome Trust Clinical Research Facility

Birmingham, West Midlands, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

189413

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.